RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Primary Peritoneal Cancer
Related studies linked through entity extraction aliases.
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE2
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
- Status
- RECRUITING
- Phase
- N/A
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
- Status
- TERMINATED
- Phase
- PHASE3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Status
- RECRUITING
- Phase
- PHASE3
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
- Status
- TERMINATED
- Phase
- PHASE3
A Beta-only IL-2 ImmunoTherapY Study
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
- Status
- WITHDRAWN
- Phase
- N/A
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2